Feldman, J. L., Cho, B. C., Li, W., Girard, N., Mak, M. P., Sauder, M., Bozorgmehr, F., Tan, J., Shih, J., Nguyen, D., Felip, E., Schuchard, J., Romero, T., Xia, K., Bauml, J. M., Simoes, J., Mahadevia, P. J., Wildgust, M. A., Spira, A. I. (2025). Dermatologic prophylaxis and impact on patient-reported outcomes in first-line
            <i>EGFR</i>
            -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8641